A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
- Citation:
- Neuro-oncology vol 17 (9) 1261-1269
- Year:
- 2015
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, CA33601, CA-37404, UL1 TR000135, U10 CA180821, K12 CA090628, CA-35103, CA-25224, CA-108961, P30 CA015083, U10 CA180882, CA-165962, CA31946, P50 CA165962, CA-35267
- Corr. Author:
- Authors:
- Daniel J. Ma Evanthia Galanis S. Keith Anderson David Schiff Timothy J. Kaufmann Patrick J. Peller Caterina Giannini Paul D. Brown Joon H. Uhm Steven McGraw Kurt A. Jaeckle Patrick J. Flynn Keith L. Ligon Jan C. Buckner Jann N. Sarkaria
- Networks:
- LAPS-MA036, LAPS-MN026, MN017, SANFORD, VA009
- Study
- NCCTG-N057K
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1,2
- Keywords:
- everolimus, FLT-PET, glioblastoma, mTOR